Mechanism for the isotype dependence of antibody-mediated toxicity in Cryptococcus neoformans-infected mice

Journal of Immunology

Volumn 164, Issue 8, 2000, Pages 4367-4374

  Lendvai, Nikoletta ^a   Qu, Xiao Wu ^b   Hsueh, Wei ^b   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FC RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G3; MONOCLONAL ANTIBODY; THROMBOCYTE ACTIVATING FACTOR;

ACUTE TOXICITY; ANIMAL MODEL; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; CROSS LINKING; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

EID: 0034655219     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.8.4367     Document Type: Article

References (60)

1. Casadevall, A. 1999. Passive antibody therapies: progress and continuing challenges. Clin. Immnnol. 93:5.
2. Wing, M. G., T. Moreau, J. Greenwood, R. M. Smith, G. Hale, J. Isaacs, H. Waldmann, P. J. Lachmann, and A. Compston. 1996. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcγRIII) and CD1 1a/CD18 (LFA-1) on NK cells. J. Clin. Invest. 98:2819.
3. Parlevliet, K. J., I. J. ten Berge, S. L. Yong, J. Surachno, J. M. Wilmink, and P. T. Schellekens. 1994. In vivo effects of IgA and IgG2a anti-CD3 isotype switch variants. J. Clin. Invest. 93:2519.
4. Currie, B. P., and A. Casadevall. 1994. Estimation of the prevalence of cryptococcal infection among HIV infected individuals in New York City. Clin. Infect. Dis. 19:1029.
5. Cherniak, R., and J. B. Sundstrom. 1994. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect. Immun. 62:1507.
6. Lee, S. C., A. Casadevall, and D. W. Dickson. 1996. Immunohistochemical localization of capsular polysaccharide antigen in the central nervous system cells in cryptococcal meningoencephalitis. Am. J. Pathol. 148:1267.
7. Buchanan, K. L., and J. W. Murphy. 1998. What makes Cryptococcus neoformans a pathogen? Emerg. Infect. Dis 4:71.
8. Lendvai, N., and A. Casadevall. 1999. Antibody mediated toxicity in Cryptococcus neoformans infection: mechanism and relationship to antibody isotype. J. Infect. Dis. 180:791.
9. Lendvai, N., A. Casadevall, Z. Liang, D. L. Goldman, J. Mukherjee, and L. Zuckier. 1998. Effect of immune mechanisms on the pharmacokinetics and organ distribution of cryptococcal polysaccharide. J. Infect. Dis. 177:1647.
10. Goldman, D. L., S. C. Lee, and A. Casadevall. 1995. Tissue localization of Cryptococcus neoformans glucuronoxy lomannan in the presence and absence of specific antibody. Infect. Immun. 63:3448.
11. Savoy, A. C., D. M. Lupan, P. B. Mananlo, J. S. Roberts, A. M. Schlageter, L. C. Weinhold, and T. R. Kozel. 1997. Acute lethal toxicity following passive immunization for treatment of murine cryptococcosis. Infect. Immun. 65:1800.
12. Malavasi, F., C. Tetta, A. Funaro, G. Bellone, E. Ferrero, A. C. Franzone, P. Dellabona, R. Rusci, L. Matera, and G. Camussi. 1986. Fc receptor triggering induces expression of surface activation antigens and release of platelet-activating factor in large granular lymphocytes, Proc. Natl. Acad. Sci. USA 83:2443.
13. Sanchez-Crespo, M., F. Alonso, and J. Egido. 1980. Platelel-activaing factor in anaphylaxis and phagocytosis. I. Release from human peripheral polymorphonuclears and monocytes during stimulation by ionophore A23187 and phagocytosis but not from degranulating basophils. Immunology 40:645.
14. Virella, G., M. F. Lopes-Virella, C. Shuler, T. Sherwood, G. A. Espinoza, P. Winocour, and J. A. Coldwell. 1983. Release of PAF by human polymorphonuclear leukocytes stimulated by immune complexes bound to Sepharose particles and human crythrocytes. Immunology 50:43.
15. Camussi, G., C. Tetta, F. Bussolino, F. Caligaris Cappio, R. Coda, C. Masera, and G. Segeloni. 1981. Mediators of immune-complex-induced aggregation of polymorphonuclear neutrophils. II. Platelet-activating factor as the effector substance of immune-induced aggregation. Int. Arch. Allergy Appl. Immun. 64:25.
16. Sanchez-Crespo, M., F. Alonso, P. Inarrea, V. Alvarez, and J. Egido. 1982. Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism. Immunopharmacology 4:173.
17. Feuerstein, G., and A. L. Siren. 1988. Platelet-activating factor and shock. Prog. Biochem. Pharmacol. 22:181.
18. McManus, L. M., D. J. Hanahan, C. A. Demopoulos, and R. N. Pinckard. 1980. Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J. Immunol 124:2919.
19. Camussi, G., C. Tetta, M. C. Deregibus, F. Bussolino, G. Segoloni, and A. Vercellone. 1982. Platelet-activating factor (PAF) in experimentally-induced rabbit acute serum sickness: role of busophil-derived PAF in immune complex deposition. J. Immunol. 128:86.
20. Inarrea, P., F. Alonso, and M. Sanchez-Crespo. 1983. Platelet-activating factor: an effector substance of the vasopermeability changes induced by the infusion of immune aggregates in the mouse. Immunopharmacology 6:7.
21. Doebber, T. W., M S. Wu, and T. Y. Shen. 1984. Platelet activating factor intravenous infusion in rats stimulates vascular lysosomal hydrolase secretion independent of blood neutrophils. Biochem. Biophys. Res. Commun. 124:980.
22. Hazenbos, W. L., I. A. Heijnen, D. Meyer, F. M. Hofhuis, C. R. Renardel de Lavalette, R. E. Schmidt, P. J. Capel, J. G. van der Winkel, J. E. Gessner, et al. 1998. Murine IgG1 complexes trigger immune effector functions predominantly via FcγRIII (CDI6). J. Immunol. 161:3026.
23. Miyajima, I., D. Dombrowicz, T. R. Martin, J. V. Ravetch, J. P. Kinet, and S. J. Galli. 1997. Systemic anaphylaxis in the mouse can be mediated largely through IgG1 and FcγRIII: assessment of the cardiopulmonary changes, mast cell degranulation, and death associated with active or IgE-or IgG1-dependent passive anaphylaxis. J. Clin. Invest. 99:901.
24. Gavin, A. L., N. Barners, H. M. Dijstelbloem, and P. M. Hogarth. 1998. Cutting Edge: identification of the mouse IgG3 receptor: implications for antibody effector function at the interface between innate and adoptive immunity. J. Immunol. 160:20.
25. Hoffman, T., A. K. Tripathi, Y. L. Lee, E. Bonvini, and B. Golding 1992. Inflammatory mediator release from human monocytes via immobilized Fc receptors: its potential role in adverse reactions to systemic monoclonal antibody therapy. Transplantation 54:343.
26. Marsh, C. B., M. D. Wewers, L. C. Tan, and B. H. Rovin. 1997. Fc-gamma receptor cross-linking induces peripheral blood mononuclear cell monocyte chemoattractant protein-1 expression. J. Immunol. 158:1078.
27. Marsh, C. B., M. P. Lowe, B. H. Rovin, J. M. Parker, Z. Liao, D. L. Knoell, and M. D. Wewers. 1998. Lymphocytes produce IL-1β in response to Fcγ Receptor cross-linking: effects on parenchymal IL-8 release. J. Immunol. 160:3942.
28. Warren, J. S. 1992. Relationship between interleukin-1b and platelet-activating factor in the pathogenesis of acute immune complex alveolitis in the rat. Am. J. Pathol. 141:551.
29. Warren, J. S., K. R. Yabroff, D. G. Remick, S. L. Kunkel, S. W. Chensue, R. G. Kunkel, K. J. Johnson, and P. A. Ward. 1989. Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J. Clin. Invest. 84:1873.
30. Shanley, T. P., H. Schmal, R. L. Warner, E. Schmid, H. P. Friedl, and P. A. Ward. 1997. Requirement for C-X-C chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant) in IgG immune complex-induced lung injury. J. Immunol. 158:3439.
31. Shanley, T. P., H. Schmal, H. P. Friedl, M. L. Jones, and P. A. Ward. 1995 Role of macrophage inflammatory protein-1 α (MIP-1a) in acute lung injury in rats. J. Immunol. 154:4793.
32. Zhang, Y., B. F. Ramos, and B. A. Jakschik. 1992. Neutrophil recruitment by tumor necrosis factor from mast cells in immune complex peritonitis. Science 258:1957.
33. Warren, J. S., P. A. Barton, D. M. Mandel, and K. Matrosic. 1990. Intrapulmonary tumor necrosis factor triggers local platelet-activating factor production in rat immune complex alveolitis. Lab. Invest. 63:746.
34. Yuan, R., A. Casadevall, G. Spira, and M. D. Scharff. 1995. Isotype switching from IgG3 to IgG1 converts a non-protective murine antibody to C. neoformans into a protective antibody. J. Immunol 154:1810.
35. Franzot, S. P., J. Mukherjee, R. Cherniak, L. Chen, J. S. Hamdan, and A. Casadevall. 1998. Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes. Infect. Immun. 66:89.
36. Dromer, F., S. Mathoulin, B. Dupont, and A. Laporte. 1996. Epidemiology of cryptococcosis in France: a 9-year survey (1985-1993). Clin. Infect. Dis. 23:82.
37. Cherniak, R., H. Reiss, and S. Turner. 1982. A galactoxylomannan antigen of Cryptococcus neoformans serotype A. Carbohydr. Res. 103:239.
38. Miyazaki, T., S. Kohno, K. Mitsutake, S. Maesaki, K. Tanaka, and K. Hara. 1995. (1→3)-β-D-glucan in culture fluid of fungi activates factor G. a limulus coagulation factor. J. Clin. Lab. Anal. 9:334.
39. Mozaffarian, N., J. W. Berman, and A. Casadevall. 1995. Immune complexes increase nitric oxide production by interferon-γ-stimulated murine macrophagelike J774.16 cells. J. Leukocyte Biol. 57:657.
40. Casadevall, A., J. Mukherjee, and M. D. Scharff. 1992. Monoclonal antibody ELISAs for cryptococcal polysaccharide. J. Immunol. Methods 154:27.
41. Qu, X., L. Huang, T. Burthart, S. E. Crawford, M. S. Caplan, and W. Hsueh. 1996. Endotoxin induces PAF production in the rar ileum: quantitation of tissue PAF by an improved method. Prostaglandins 51:249.
42. Hsueh, W., F. Gonzalez-Crussi, and J. L. Arroyave. 1987. Platelet-activating factor: an endogenous mediator for bowel necrosis in endotoxemia. FASEB J. 1:403.
43. Tavares de Lima, W., A. A. Steil, M. Russo, N. Starobinas, C. F. Teixeira, and S. Jancar. 1998. Lipid mediators, tumor necrosis factor and nitric oxide and their interactions in immune-complex-induced lung injury. Eur. J. Pharmacol. 358:69.
44. Berger, S., H. Ballo, and H. J. Stutte. 1996. Immune complex-induced interleukin-6, interleukin-10 and prostaglandin secretion by human monocytes: a network of pro-and anti-inflammatory cytokines dependent on the antigen: antibody ratio. Eur. J. Immunol. 26:1297.
45. Titheradge, M. A. 1999. Nitric oxide in septic shock. Biochem. Biophys. Acta 1411:437.
46. Qu, X. W., R. A. Rozenfeld, W. Huang, S. E. Crawford, F. Gonzalez-Crussi, and W. Hsueh. 1998. Interaction of platelet-activating factor, spleen and atrial natriuretic peptide in plasma volume regulation during endotoxaemia in rats. J. Physiol. 512:203.
47. Diamond, B., and D. E. Yelton. 1981. A new Fc receptor on mouse macrophages binding IgG3. J. Exp. Med. 153:514.
48. Yuan, R., G. Spira, J. Oh, M. Paizi, A. Casadevall, and M. D. Scharff. 1998. Isotype switching increases antibody protective efficacy to Cryptococcus neoformans infection in mice. Infect. Immun. 66:1057.
49. Yuan, R., R. Clynes, J. Oh, J. V. Ravetch, and M. D. Scharff. 1998. Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor function and IgG subclass. J. Exp. Med. 187:1.
50. Vecchiarelli, A., C. Retini, D. Pietrella, C. Monari, C. Tascini, T. Beccari, and T. R. Kozel. 1995. Downregulation by cryptococcal polysaccharide of tumor necrosis factor α and interleukin-1β secretion from human monocytes. Infect. Immun. 63:2919.
51. Retini, C., A. Vecchiarelli, C. Monari, C. Tascini, F. Bistoni, and T. R. Kozel. 1996. Capsular polysaccharide of Cryptococcus neoformans induces proinflammatory cytokine release by human neutrophils. Infect. Immun. 64:2897.
52. Vecchiarelli, A., C. Retini, A. Casadevall, C. Monari, D. Pietrella, and T. R. Kozel. 1998. Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular polysaccharide material of Cryptococcus neoformans. Infect. Immun. 66:4324.
53. Delfino, D., L. Cianci, M. Migliardo, G. Mancuso, V. Cusumano, C. Corradini, and G. Tett. 1996. Tumor necrosis factor-inducing activities of Cryptococcus neoformans components. Infect. Immun. 64:5199.
54. Berg, D. J., R. Kuhn, K. Rajewsky, W. Muller, S. Menon, N. Davidson, G. Grunig, and D. Rennick. 1996. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. Eur. J. Immunol. 26:1297.
55. Blanque, R., C. Meakin, S. Millet, and C. R. Gardner. 1999. Dual mechanisms of action of interferon-γ in potentiating responses to LPS in mice: IL-1, TNFα, and IL-6 production in serum and hypothermia. Gen. Pharmacol. 32:453.
56. Hanamura, T., E. Asakura, and T. Tanabe. 1997. Macrophage colony-stimulating factor (M-CSF) augments cytokine induction by lipopolysaccharide (LPS)-stimulation and by bacterial infections in mice. Immunopharmacology 37:15.
57. Leon, L. R., W. Kozack, K. Rudolph, and M. J. Kluger. 1999. An antipyretic role for interleukin-10 in LPS fever in mice. Am. J. Physiol. 276.-R81.
58. Ohno, N., N. Asada, Y. Adachi, and T. Yadomae. 1995. Enhancement of LPS triggered TNF-α (tumor necrosis factor α) by (1→3)-β-glucans in mice. Biol. Pharm. Bull. 18:126.
59. Salkowski, C. A., R. Neta, T. A. Wynn, G. Strassmann, N. van Rooijen, and S. N. Vogel. 1995. Effect of liposome-mediated macrophage depletion on LPS-induced cytokine gene expression and radioprotection. J. Immunol. 155:3168.
60. Young, J. M., P. J. Moloney, S. N. Jubb, and J. S. Clark. 1985. Pharmacological investigation of the mechanisms of platelet-activating factor induced mortality in the mouse. Prostaglandins 30:545.